Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of SKI-606 in Subjects with Advanced or Metastatic Breast Cancer
2005-005543-25Phase 2Completed
- Sponsor
- Wyeth
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bosutinib in breast cancer, sponsored by Wyeth. Primary endpoints: Progression-free survival at 16 weeks (PFS16) and Safety profile of SKI-606 400 mg/day. Started Aug 2006; status: completed.
02
Drugs
bosutinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-005543-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005543-25.